Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 49.

Pentheroudakis, G; Cardoso, F; Arnold, D; Sessa, C; Peters, S; Horwich, A; Pavlidis, N; Stahel, R; Cervantes, A (2015). The ESMO guideline strategy: an identity statement and reflections on improvement. Annals of Oncology, 26 Suppl:v1-v7.

Eberhardt, W E E; De Ruysscher, D; Weder, W; Le Péchoux, C; De Leyn, P; Hoffmann, H; Westeel, V; Stahel, R; Felip, E; Peters, S (2015). 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 26(8):1573-1588.

Stahel, R; Bogaerts, J; Ciardiello, F; de Ruysscher, D; Dubsky, P; Ducreux, M; Finn, S; Laurent-Puig, P; Peters, S; Piccart, M; Smit, E; Sotiriou, C; Tejpar, S; Van Cutsem, E; Tabernero, J (2015). Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 41(2):129-135.

Popescu, R; Ciardiello, F; Stahel, R (2014). Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. Annals of Oncology, 25(9):1865.

Curioni-Fontecedro, A; Soldini, D; Seifert, B; Eichmueller, T; Korol, D; Moch, H; Weder, W; Stahel, R (2014). A Comprehensive Analysis of Markers for Neuroendocrine Tumors of the Lungs Demonstrates Estrogen Receptor Beta to be a Prognostic Markers in SCLC Male Patients. Journal of Cytology & Histology:5:268.

Patton, S; Normanno, N; Blackhall, F; Murray, S; Kerr, K M; Dietel, M; Filipits, M; Benlloch, S; Popat, S; Stahel, R; Thunnissen, E (2014). Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer, 111(2):413-420.

Ciardiello, F; Arnold, D; Casali, P G; Cervantes, A; Douillard, J-Y; Eggermont, A; Eniu, A; McGregor, K; Peters, S; Piccart, M; Popescu, R; Van Cutsem, E; Zielinski, C; Stahel, R (2014). Delivering Precision Medicine in Oncology Today and in Future-The Promise and Challenges of Personalised Cancer Medicine: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 25(9):1673-1678.

Besse, B; Adjei, A; Baas, P; Meldgaard, P; Nicolson, M; Paz-Ares, L; Reck, M; Smit, E F; Syrigos, K; Stahel, R; Felip, E; Peters, S (2014). 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 25(8):1475-1484.

Vansteenkiste, J; Crinò, L; Dooms, C; Douillard, J Y; Faivre-Finn, C; Lim, E; Rocco, G; Senan, S; Van Schil, P; Veronesi, G; Stahel, R; Peters, S; Felip, E (2014). 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 25(8):1462-1474.

Kerr, K M; Bubendorf, L; Edelman, M J; Marchetti, A; Mok, T; Novello, S; O'Byrne, K; Stahel, R; Peters, S; Felip, E (2014). Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9):1681-1690.

Peters, Solange; Stahel, R A (2014). Successes and limitations of targeted cancer therapy. Basel: Karger.

Zimmermann, S; Curioni-Fontecedro, Alessandra; Stahel, R; Peters, S (2013). Lung Cancer. In: Dicato, M A. Side Effects of Medical Cancer Therapy. - Prevention and Treatment. London: Springer-Verlag, 119-138.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

Petrausch, U; Schuberth, P C; Hagedorn, C; Soltermann, A; Tomaszek, S; Stahel, R; Weder, W; Renner, C (2012). Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer, 12:615.

Fischer, B; Frei, C; Moura, U; Stahel, R; Felley-Bosco, E (2012). Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer, 78(1):23-29.

Pavlidis, N; Stahel, R; Pentheroudakis, G; Cervantes, A (2012). ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines. Annals of Oncology, 23(Supp 7):vii7-vii10.

Collaud, S; Lardinois, D; Tischler, V; Steinert, H C; Stahel, R; Weder, W (2012). Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 41(3):612-616.

Brodowicz, T; Ciuleanu, T; Crawford, J; Filipits, M; Fischer, J R; Georgoulias, V; Gridelli, C; Hirsch, F R; Jassem, J; Kosmidis, P; Krzakowski, M; Manegold, C; Pujol, J L; Stahel, R; Thatcher, N; Vansteenkiste, J; Minichsdorfer, C; Zöchbauer-Müller, S; Pirker, R; Zielinski, C C (2012). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology, 23(5):1223-1229.

Pavlidis, N; Vermorken, J B; Stahel, R; Bernier, J; Cervantes, A; Pentheroudakis, G; Audisio, R A; Costa, A (2012). Undergraduate training in oncology: An ESO continuing challenge for medical students. Surgical Oncology, 21(1):15-21.

Stahel, R; Thatcher, N; Früh, M; Le Péchoux, C; Postmus, P E; Sorensen, J B; Felip, E (2011). 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Annals of Oncology, 22(9):1973-1980.

Pfreundschuh, M; Kuhnt, E; Trümper, L; Osterborg, A; Trneny, M; Shepherd, L; Gill, D S; Walewski, J; Pettengell, R; Jaeger, U; Zinzani, P L; Shpilberg, O; Kvaloy, S; de Nully Brown, P; Stahel, R; Milpied, N; López-Guillermo, A; Poeschel, V; Grass, S; Loeffler, M; Murawski, N (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, 12(11):1013-1022.

Salazar, F; Molina, M A; Sanchez-Ronco, M; Moran, T; Ramirez, J L; Sanchez, J M; Stahel, R; Garrido, P; Cobo, M; Isla, D; Bertran-Alamillo, J; Massuti, B; Cardenal, F; Manegold, C; Lianes, P; Trigo, J M; Sanchez, J J; Taron, M; Rosell, R (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1):84-91.

Pavlidis, N; Stahel, R; Hansen, H; Cervantes, A (2011). Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines. Annals of Oncology, 22(Suppl 6):vi7-vi11.

Felip, E; Gridelli, C; Baas, P; Rosell, R; Stahel, R (2011). Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology, 22(7):1507-1519.

Opitz, I; Erne, B V; Demirbas, S; Jetter, A; Seifert, Burkhardt; Stahel, R; Weder, W (2011). Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. Journal of Thoracic and Cardiovascular Surgery, 141(1):65-71.

Frei, C; Opitz, I; Soltermann, A; Fischer, B; Moura, U; Rehrauer, H; Weder, W; Stahel, R; Felley-Bosco, E (2011). Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis, 32(9):1324-1332.

Gridelli, C; Stahel, R; Besse, B; Ciardiello, F; Felip, E; Gasparini, S; Graziano, P; Rossi, A; de Marinis, F (2011). Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer, 74(3):544-548.

Scherpereel, A; Astoul, P; Baas, P; Berghmans, T; Clayson, H; de Vuyst, P; Dienemann, H; Galateau-Salle, F; Hennequin, C; Hillerdal, G; Le Pe'choux, C; Mutti, L; Pairon, J C; Stahel, R; van Houtte, P; van Meerbeeck, J; Waller, D; Weder, W (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 13(10):C23-C45.

Pavlidis, N; Hansen, H; Stahel, R (2010). ESMO Clinical Practice Guidelines: development, implementation and dissemination. Annals of Oncology, 21(Suppl):v7-v8.

Weder, W; Collaud, S; Eberhardt, W E E; Hillinger, S; Welter, S; Stahel, R; Stamatis, G (2010). Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 139(6):1424-1430.

Stahel, R; Baas, P; Faivre-Finn, C; Dooms, C; Passlick, B; Mazières, J; Cappuzzo, F; Früh, M; Sorensen, J B; Blackhall, F; Taron, M; Gridelli, C; O'Byrne, K; Rosell, R (2010). Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer, 68(1):121-124.

Pirker, R; Herth, F J F; Kerr, K M; Filipits, M; Taron, M; Gandara, D; Hirsch, F R; Grunenwald, D; Popper, H; Smit, E; Dietel, M; Marchetti, A; Manegold, C; Schirmacher, P; Thomas, M; Rosell, R; Cappuzzo, F; Stahel, R (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology, 5(10):1706-1713.

Scherpereel, A; Astoul, P; Baas, P; Berghmans, T; Clayson, H; de Vuyst, P; Dienemann, H; Galateau-Salle, F; Hennequin, C; Hillerdal, G; Le Péchoux, C; Mutti, L; Pairon, J C; Stahel, R; van Houtte, P; van Meerbeeck, J; Waller, D; Weder, W (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma. European Respiratory Journal, 35:479-495.

Martinelli, G; Schmitz, S F H; Utiger, U; Cerny, T; Hess, U; Bassi, S; Okkinga, E; Stupp, R; Stahel, R; Heizmann, M; Vorobiof, D; Lohri, A; Dietrich, P Y; Zucca, E; Ghielmini, M (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28(29):4480-4484.

Pavlidis, N; Gatzemeier, W; Popescu, R; Stahel, R; Pinedo, H; Cavalli, F; Costa, A (2010). The masterclass of the european school of oncology: the 'key educational event' of the school. European Journal of Cancer, 46(12):2159-2165.

Pavlidis, N; Hansen, H; Stahel, R (2009). ESMO clinical recommendations: using the easier and faster approach to oncology guidelines. Annals of Oncology, 20(Suppl):7-9.

Carteni, G; Manegold, C; Martin Garcia, G; Siena, S; Zielinski, C C; Amadori, D; Liu, Y; Blatter, J; Visseren-Grul, C; Stahel, R (2009). Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer, 64(2):211-218.

Weder, W; Opitz, I; Stahel, R (2009). Multimodality strategies in malignant pleural mesothelioma. Seminars in Thoracic and Cardiovascular Surgery, 21(2):172-176.

Stahel, R; Felley-Bosco, E; Opitz, I; Weder, W (2008). Mesothelioma. In: Hansen, H. Lung Cancer Therapy Annual 6. New York: Informa Healthcare USA, Inc., 205-222.

Rosell, R; Manegold, C; Moran, T; Garrido, P; Blanco, R; Lianes, P; Stahel, R; Trigo, J M; Wei, J; Taron, M (2008). Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 9(Supplement):S76-S82.

Pentheroudakis, G; Stahel, R; Hansen, H; Pavlidis, N (2008). Heterogeneity in cancer guidelines: should we eradicate or tolerate? Annals of Oncology, 19(12):2067-2078.

D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.

Opitz, I; Soltermann, A; Abaecherli, M; Hinterberger, M; Probst-Hensch, N; Stahel, R; Moch, H; Weder, W (2008). PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-Thoracic Surgery, 33(3):502-506.

Langenegger, P; Jäckle, R; Stahel, R; Tiziani, C (2008). Quellen und Nutzung von wissenschaftlicher Erkenntnis in der Praxis. HR Today: das Schweizer Human Resource Management-Journal, 5:64-66.

Belyanskaya, L L; Ziogas, A; Hopkins-Donaldson, S; Kurtz, S; Simon, H U; Stahel, R; Zangemeister-Wittke, U (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer, 60(3):355-365.

Opitz, I; Kestenholz, P; Lardinois, D; Müller, M; Rousson, V; Schneiter, D; Stahel, R; Weder, W (2006). Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. European Journal of Cardio-Thoracic Surgery, 29(4):579-584.

Lardinois, D; Jung, F J; Opitz, I; Rentsch, K; Latkoczy, C; Vuong, V; Varga, Z; Rousson, V; Günther, D; Bodis, S; Stahel, R; Weder, W (2006). Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. Journal of Thoracic and Cardiovascular Surgery, 131(3):697-703.

Bouchardy, C; Raymond, L; de Wolf, C; Abel, T; Ackermann-Liebrich, Ursula; Goldhirsch, A; Gutzwiller, Felix; Haefliger, J M; Levi, F; Noseda, G; Obrist, R; Paccaud, Fred; Probst-Hensch, Nicole; Rougemont, A; Stahel, R; Tubiana, M; Weber, W (2001). Prise de position en faveur du dépistage mammographique du cancer du sein en Suisse. Schweizerische Ärztezeitung (SÄZ), 82(12):595-603.

Bouchardy, C; Raymond, L; de Wolf, C; Abel, T; Ackermann-Liebrich, Ursula; Goldhirsch, A; Gutzwiller, Felix; Haefliger, J M; Levi, F; Noseda, G; Obrist, R; Paccaud, Fred; Probst-Hensch, Nicole; Rougemont, A; Stahel, R; Tubiana, M; Weber, W (2001). Stellungnahme zur Wirksamkeit des Mammographiescreenings in der Schweiz. Schweizerische Ärztezeitung (SÄZ), 82(13):655-661.

This list was generated on Tue Jul 17 20:23:10 2018 CEST.